Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 3 | 5 |
| 1.1 List of Tables | 5 | 1 |
| 1.2 List of Figures | 6 | 2 |
| 2 Downstream Processing: Introduction | 8 | 1 |
| 2.1 GBI Research Report Guidance | 8 | 1 |
| 3 Downstream Processing Market Overview | 9 | 7 |
| 3.1 Overview of Biopharmaceuticals | 9 | 1 |
| 3.1.1 Cytokines | 9 | 1 |
| 3.1.2 Enzymes | 9 | 1 |
| 3.1.3 Hormones | 9 | 1 |
| 3.1.4 Clotting Factors | 9 | 1 |
| 3.1.5 Vaccines | 10 | 1 |
| Monoclonal Antibodies | 10 | 1 |
| 3.1.7 Cell Therapies | 10 | 1 |
| 3.1.8 Antisense Drugs | 10 | 1 |
| 3.1.9 Peptide Therapeutics | 10 | 2 |
| 3.2 Overview of Downstream Processing in Biopharmaceuticals | 12 | 1 |
| 3.2.1 A Typical Downstream Processing: | 13 | 1 |
| 3.2.1.1 Initial Clarification | 13 | 1 |
| 3.2.1.2 Initial Capture | 13 | 1 |
| 3.2.1.3 Intermediate Purification | 13 | 1 |
| Major Check Point during Down Stream Processing | 14 | 1 |
| 3.2.2.1 Clear Project Goal | 14 | 1 |
| 3.2.2.2 Check of Process Robustness | 14 | 1 |
| 3.2.2.3 Validated Down Scale | 14 | 1 |
| 3.2.2.4 Virus Clearance | 14 | 1 |
| 3.2.2.5 Virus Panel | 14 | 1 |
| 3.2.2.6 Spiking Studies | 14 | 1 |
| 3.3 Overview of Downstream Industry | 15 | 1 |
| 4 Downstream Processing : Role of Downstream Processing in the Biopharmaceutical Industry | 16 | 11 |
| 4.1 Comparison of Upstream Processing and Downstream Processing | 18 | 1 |
| 4.2 Major Reagents, Reagent Suppliers and Reagent Market Related To Downstream Processing | 19 | 1 |
| Major Reagents | 19 | 1 |
| 4.2.1.1 Protein Extraction Kit /Reagents | 19 | 1 |
| 4.2.1.2 Filter Media | 19 | 1 |
| 4.2.1.3 Protein A Media | 19 | 1 |
| 4.2.1.4 Balanced Salt Solutions | 19 | 1 |
| 4.2.1.5 Biological Buffers | 19 | 1 |
| 4.2.1.6 Polyethylene Glycol (PEG) | 19 | 1 |
| 4.2.1.7 Glycyl-glycine | 19 | 1 |
| 4.2.1.8 Resin / Agarose | 20 | 1 |
| 4.2.2 Reagent Suppliers | 20 | 2 |
| 4.2.3 Reagent Market | 22 | 4 |
| 4.3 Major Equipment Suppliers | 26 | 1 |
| 5 Downstream Processing: Downstream Processing Market for CMOs | 27 | 3 |
| 5.1 Global CMO Market Overview | 27 | 1 |
| 5.2 CMO Biopharmaceuticals Market Characterization | 27 | 2 |
| 5.3 CMO Market Size for Downstream Processing | 29 | 1 |
| 6 Downstream Processing : Challenges and Unmet Needs in Downstream Bioprocess | 30 | 6 |
| 6.1 Challenges | 30 | 1 |
| 6.1.1 Chromatographic Capture | 30 | 1 |
| 6.1.2 Reducing the Purification Steps | 30 | 1 |
| 6.1.3 Titer increment /Capacity Bottleneck | 31 | 1 |
| 6.1.4 Virus Clearances | 31 | 1 |
| 6.1.5 Scaling Up | 31 | 1 |
| 6.2 Unmet Needs | 32 | 1 |
| 6.2.1 Unmet Medical Needs | 32 | 1 |
| 6.2.2 Realistic Achievement of Economies of Scale | 33 | 1 |
| 6.2.3 Technological Development of Disposables at Large Scale | 34 | 1 |
| 6.2.4 Reagent Cost and Their Effectiveness | 35 | 1 |
| 7 Downstream Processing : Emerging Technologies and their Implication | 36 | 14 |
| 7.1 Disposable Technology / Single Use Technology | 36 | 3 |
| 7.1.1 Use of Single Use Technology in Downstream Operations | 39 | 1 |
| 7.1.2 Major Benefits of Single use Technology | 40 | 1 |
| 7.1.3 Major Challenges in Single Use Technology | 41 | 1 |
| 7.1.4 Some Recent Products Developed By Major Firms | 42 | 1 |
| 7.2 Membrane Chromatography | 42 | 2 |
| 7.3 Multi-Column Chromatography | 44 | 1 |
| 7.3.1 Advantages | 44 | 1 |
| 7.3.2 Drawbacks | 44 | 1 |
| 7.3.3 Applications | 45 | 1 |
| 7.4 Aqueous Two Phase System | 45 | 1 |
| 7.5 Tangential Flow Filtration | 45 | 1 |
| 7.5.1 Tangential Flow Filtration Applications | 46 | 1 |
| 7.5.1.1 Ultrafiltration Applications | 46 | 1 |
| 7.5.1.2 Microfiltration Applications | 46 | 1 |
| 7.5.2 Few Products Developed By Major Firms | 47 | 1 |
| 7.6 Monoliths | 47 | 1 |
| 7.7 Expanded-Bed Adsorption (EBA) Chromatography | 47 | 1 |
| 7.7.1 Applications | 48 | 1 |
| 7.8 Mixed-Mode Chromatography | 48 | 2 |
| 8 Downstream Processing : Industry Analysis | 50 | 7 |
| 8.1 Key Drivers and Restraints | 50 | 1 |
| 8.1.1 Key Drivers of Downstream Processing Market | 50 | 1 |
| 8.1.1.1 Changing Focus towards Downstream Processing | 50 | 1 |
| 8.1.1.2 Multicolumn Chromatography Will Dominate the Market | 50 | 1 |
| 8.1.1.3 Single Use Technologies will be Widely Used | 50 | 1 |
| 8.1.1.4 Increasing Size of CMOs in Emerging Market | 50 | 1 |
| 8.1.2 Key Restraints of Downstream Processing Market | 51 | 1 |
| 8.1.2.1 High Cost | 51 | 1 |
| 8.1.2.2 Less Technical Expertise | 51 | 1 |
| 8.1.2.3 Reduced Number of Purification Runs | 51 | 1 |
| 8.2 Porter Five Forces Model for Industry Analysis | 52 | 1 |
| 8.2.1.1 Barriers to Entry | 52 | 1 |
| 8.2.1.2 Determinant of Buyers Power | 53 | 1 |
| 8.2.1.3 Determinant of Suppliers Power | 54 | 1 |
| 8.2.1.4 Threat of Substitute Products | 54 | 1 |
| 8.2.1.5 Rivalry among Existing Firms | 54 | 1 |
| 8.3 Impact of Environmental Factors on the Industry | 55 | 1 |
| 8.3.1 International Economy Impact | 55 | 1 |
| 8.3.2 The Natural Environment Impact | 55 | 1 |
| 8.3.3 Technological Impact | 55 | 1 |
| 8.3.4 Political or Governmental Impact | 55 | 1 |
| 8.3.5 Demographic Structure | 56 | 1 |
| 8.3.6 Social Structure | 56 | 1 |
| 8.4 Major Events and Their Impact Analysis | 56 | 1 |
| 9 Downstream Processing: Competitive Landscape | 57 | 31 |
| 9.1 Market Dynamics of Downstream Processing and Impact | 57 | 1 |
| 9.1.1 Market Structure | 57 | 1 |
| 9.1.2 Competitive Analysis of Major CMO Firms | 58 | 1 |
| 9.1.3 Competitive Analysis of Equipment and Reagent Industry | 59 | 1 |
| 9.2 Key Equipment Players | 60 | 1 |
| 9.2.1 Pall Corporation | 60 | 1 |
| 9.2.1.1 Business Overview | 60 | 1 |
| 9.2.1.2 SWOT Analysis | 61 | 1 |
| 9.2.1.3 M&A Deals | 62 | 1 |
| 9.2.2 Milipore | 63 | 1 |
| 9.2.2.1 Business Overview | 63 | 1 |
| 9.2.2.2 SWOT Analysis | 64 | 1 |
| 9.2.2.3 M&A Deals | 65 | 1 |
| 9.2.3 Sartorius | 66 | 1 |
| 9.2.3.1 Business Overview | 66 | 1 |
| 9.2.3.2 SWOT Analysis | 67 | 1 |
| 9.2.3.3 M&A Deals | 68 | 1 |
| 9.2.4 3M Purification Inc. | 69 | 1 |
| 9.2.4.1 Business Overview | 69 | 1 |
| 9.2.4.2 SWOT Analysis | 70 | 1 |
| 9.2.4.3 M&A Deals | 70 | 1 |
| 9.3 Key Reagent Players | 71 | 1 |
| 9.3.1 Life Technologies | 71 | 1 |
| 9.3.1.1 Business Overview | 71 | 1 |
| 9.3.1.2 SWOT Analysis | 72 | 1 |
| 9.3.1.3 M&A Deals | 73 | 1 |
| 9.3.2 Sigma Aldrich | 74 | 1 |
| 9.3.2.1 Business Overview | 74 | 1 |
| 9.3.3 SWOT Analysis | 75 | 1 |
| 9.3.4 M&A Deals | 75 | 2 |
| 9.4 Key CMO Players | 77 | 1 |
| 9.4.1 Lonza | 77 | 1 |
| 9.4.1.1 Business Overview | 77 | 1 |
| 9.4.1.2 SWOT Analysis | 78 | 1 |
| 9.4.1.3 M&A Deals | 79 | 1 |
| 9.4.2 Boehringer Ingelheim | 80 | 1 |
| 9.4.2.1 Business Overview | 80 | 1 |
| 9.4.3 SWOT Analysis | 81 | 1 |
| 9.4.3.1 M&A Deals | 82 | 1 |
| 9.4.4 Avecia Biotechnology | 83 | 1 |
| 9.4.4.1 Business Overview | 83 | 1 |
| 9.4.4.2 SWOT Analysis | 84 | 1 |
| 9.4.4.3 M&A Deals | 84 | 1 |
| 9.4.5 Diosynth Biotechnology | 85 | 1 |
| 9.4.5.1 Business Overview | 85 | 2 |
| 9.4.5.2 SWOT Analysis | 87 | 1 |
| 9.4.5.3 M&A Deals | 87 | 1 |
| 10 Downstream Processing : Appendix | 88 | 4 |
| 10.1 Market Definitions | 88 | 1 |
| 10.2 Abbreviations | 88 | 1 |
| 10.3 Research Methodology | 89 | 2 |
| 10.3.1 Coverage | 89 | 1 |
| 10.3.2 Secondary Research | 89 | 1 |
| 10.3.3 Primary Research | 89 | 1 |
| 10.3.4 Expert Panel Validation | 90 | 1 |
| 10.4 Contact Us | 90 | 1 |
| 10.5 Disclaimer | 90 | 1 |
| 10.6 Sources | 91 | 1 |